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Abstract. Tuberculosis (TB) infects one third of the world’s population, and new infections occur at a rate
of 1/s. Better vaccines are needed than the live mycobacterium Bacille Calmette-Guérin (BCG). Alveolar
macrophages (AMΦs) play a central role in pulmonary manifestations of TB. Targeting immunomodu-
lators to AMΦs, the first line of defense against Mycobacterium tuberculosis (Mtb), may initiate a potent
cell-mediated immune response. Muramyl dipeptide (MDP) and trehalose dibehenate (TDB) have
elicited strong immune response when delivered to the lungs as aerosols. AMΦs show toxicity in
response to some immunomodulators. The objective of this work was to screen the immunomodulators
MDP and/or TDB encapsulated in microparticles (MPs) and to evaluate certain indicators of toxicity in
human AMΦ-like cells. Poly(lactide-co-glycolide) (PLGA) MPs containing MDP and/or TDB were
prepared by spray-drying. The morphology, particle size distribution, and immunomodulator encapsu-
lation efficiency of MPs were examined. THP-1 cells were exposed to these MPs for 24 h and
characteristics of cell morphology, tumor necrosis factor-alpha (TNF-α) release, lactate dehydrogenase
(LDH), N-acetyl-β-D-glucosaminidase (NAG) and alkaline phosphatase (ALP) activity in AMΦ culture
supernatants were measured. MTT assay was used to assess the viability of cells. Spray-drying produced
low-density MPs having volume median diameters between 4 and 6 μm as measured by laser diffraction
and projected area diameter between 3 and 5 μm calculated by microscopy. More TNF-α was produced
by THP-1 cells exposed to MPs composed of PLGA-MDP or PLGA alone than PLGA-TDB. LDH
release following exposure to MPs of PLGA-MDP and PLGA alone was greater than controls. NAG
release was higher following exposure to MPs of PLGA alone or PLGA-MDP 0.1% than PLGA-TDB
(0.1% and 1.0%). Cells remained viable after exposure to MPs as per MTT assay. PLGA-MDP MPs
demonstrated statistically elevated indicators of biochemical responses in cell culture compared to
PLGA-TDB MPs, but the extent of their potential to elicit adverse effects in vivo must be studied
independently.
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INTRODUCTION
Tuberculosis (TB) caused mortality and morbidity which
included 9.2 million new cases and 1.7 million deaths in 2006,
mostly in developing countries (1). These statistics reveal that
Bacille Calmette-Guérin (BCG), the only TB vaccine used in
humans for almost a century, had limited success against this
epidemic in the developing world. In fact, BCG fails to
protect against the most common form of the disease,
pulmonary TB in adults (2). Mycobacterium tuberculosis
(Mtb), the causative agent for TB, normally enters the host
through the respiratory tract after inhalation of droplets from
an infected individual. They are taken up by antigen-
presenting cells (APCs), especially alveolar macrophages
(AMΦs), which provide the first line of immune response
for the infected individual. This may lead to a rapid
inflammatory response characterized by the release of various
antimicrobial effector molecules, including cytokines and
chemokines, and with time, to the formation of granulomas
in the lungs (3). This inflammatory response is accompanied
by a cell-mediated immune response consisting of CD4+ and
CD8+ effector T cells (4). A Th1 immune response, rather
than a Th2 response, is critical in containing the infection in
granulomas and thus preventing progression to active disease
(5).
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Certain cell wall components of Mtb are known to elicit
an immune response, one of them being mycolic acid (6); its
derivatives are known to stimulate the host inflammatory
response, leading to the protective granuloma formation (7)
and the T cell response in animal models (8). The best-
characterized mycolate, trehalose dimycolate (TDM) or cord
factor, is used as adjuvant and selectively induce a Th1
response (9). Any adjuvant system is guided by its safety,
stability, and immunogenicity.
Muramyl dipeptide (MDP) and trehalose dibehenate
(TDB), immunogenic components and synthetic analogs of
the cell wall of Mtb, are capable of eliciting a strong adjuvant
activity. TDB is a synthetic analog of TDM (10) and MDP has
the minimal chemical structure needed for adjuvant activity
similar to complete Freund’s adjuvant (11). MDP has
previously been administered with mineral oil; the oil pro-
longs its residence time in the body as a depot and enhances
the cell-mediated immune response (12). But mineral oil
leads to greater toxicity as it is not metabolized (13).
Immunization by the pulmonary route against TB has
gained considerable interest in recent years (14), as it
eliminates the requirement for needles and the associated
discomfort, while stimulating a cell-mediated immune re-
sponse. The pulmonary route being the route of infection in
humans, the lungs should be the gateway organ to confer
protection. This noninvasive route reduces the need for
medical assistance and is suitable for mass vaccination.
We have previously shown that guinea pigs exposed to
aerosols of MDP microparticles (MPs) lead to morphological
changes in AMΦ like pseudopodia formation and spreading
(15). Nagao et al. had targeted MDP to peritoneal macro-
phages (MΦs) in guinea pigs and showed that it induced
activation (16). AMΦ are the first line of defense to inhaled
foreign antigens. These antigens may cause release of
cytoplasmic enzymes which are characteristic of damaged or
lysed cells including AMΦs.
Lactate dehydrogenase (LDH), a cytoplasmic enzyme
released from damaged or lysed cells, can be used as a
marker of cytotoxicity. N-acetyl-β-D-glucosaminidase (NAG),
a lysosomal enzyme, is an indicator of increased phagocytic
activity in response to inhaled particles (17). Alkaline
phosphatase (ALP) is again a lysosomal enzyme indicative
of tissue damage. An increase in these enzymes after
exposure of AMΦs to MDP and TDB MPs can be used to
distinguish between deleterious effects and physiologic
responses. The role of TNF-α in TB is paradoxical. Although
it has been shown to have a protective role, there is also
evidence that it plays a part in tissue damage that character-
izes human disease. Potential cytotoxicity is demonstrated
directly in the viability assay (MTT) performed using cells
exposed to MDP and TDB MPs.
MATERIALS AND METHODS
Preparation of MPs Containing Immunostimulatory
Adjuvants
Poly(lactide-co-glycolide) (PLGA, lactic/glycolic ratio
75:25, MW 84.7 kDa, intrinsic viscosity 0.68 dL/g in CHCl3)
was purchased from Durect (Lactel® Absorbable Polymers,
Pelham, AL, USA). Adjuvants MDP and TDB were pur-
chased from Sigma (St. Louis, MO, USA). Dichloromethane
(DCM) was purchased from Burdick & Jackson (high-
performance liquid chromatography [HPLC] grade, Mus-
kegon, MI, USA). MPs were prepared by spray-drying a
primary emulsion. PLGAwas dissolved in DCM (0.35%, w/v)
and MDP and TDB dissolved either alone or together in
20 mM, pH 7.0 phosphate buffer. A water-in-oil emulsion
(phosphate buffer/DCM=1:20, v/v) was formed by emulsify-
ing the mixture using a probe sonicator.
The emulsion was spray-dried through a 0.7-mm diam-
eter nozzle of a Buchi mini spray-dryer (B-191 Buchi
Labortechnik AG, Flawil, Switzerland). The following con-
ditions were used: inlet temperature 65°C, outlet temperature
40°C, aspirator setting 50%, feed flow rate 7.3 mL/min, and
compressed nitrogen flow rate 600 L/h.
Characterization of Particle Morphology and Size
MPs were examined by a scanning electron microscope
(JSM 6300V SEM, JEOL USA, Peabody, NY, USA). The
surface morphology and shape were examined by spreading
particles on a conductive double-sided tape attached to
aluminum stubs and sputter-coating with gold–palladium
alloy using Polaron 5200 (Structure Probe Supplies, West
Chester, PA, USA).
Particle size distribution and median volume diameter
were measured using a laser diffraction size analyzer (Series
2600C Malvern Instruments, Malvern, UK). Briefly, MPs
were dry-mixed with sodium lauryl sulfate (SDS, Sigma) and
suspended in distilled water. The suspensions were vortex-
mixed for 1 min and sonicated for 30 s (Fisher Scientific
FS21H) to break the aggregates. It was added dropwise in a
stirred sample cell containing distilled water until the
obscuration between 15% and 30% was achieved. The
samples were directed through the monochromatic laser
(He–Ne) light beam. The analyses were carried out in
triplicate for each batch and type of MPs.
Density Determination
MP densities were evaluated by tap density and by the
relationship between mass median aerodynamic diameter
(MMAD) and median volume diameter (Dv50, 50% by
volume of particles below this value). Briefly, known quan-
tities (v×ρ) of MPs were added to a 10-mL graduated
cylinder. Tap densities of MPs were determined by measuring
the volumes occupied after 100 uniform taps on a flat surface.
The MMAD and Dv50 acquired from the Anderson cascade
impactor and laser particle size analyzer, respectively, were
used to calculate the apparent density using the equation:
MMAD ¼ Dv50 ffiffiffip :
Adjuvant Encapsulation Efficiency
About 20 mg of MPs were dissolved in 1 mL DCM and
extracted with 0.5 mL ammonium phosphate buffer (25 mM,
pH 7). The amount of MDP was analyzed by Hewlett
Packard 1100 series HPLC (Agilent Technologies, Santa
Clara, CA, USA) using the Waters Spherisorb S5 ODS2
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(4.0×250 mm) analytic column. The mobile phase consisted
of ammonium phosphate buffer and methanol (97:3). A UV-
visible detector was used at a maximum wavelength of
200 nm. The encapsulation efficiency was calculated as a
ratio of observed to theoretical MDP content.
The encapsulation efficiency of TDB in the formulations
could not be measured because of the absence of an HPLC
method for its detection.
Cell Line and MP Exposure
Human monocytic THP-1 cells were obtained from
American Type Culture Collection and cultured in complete
RPMI 1640 media (10% fetal bovine serum, 2 mM
L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose,
10 mM HEPES, 1.0 mM sodium pyruvate, and 0.05 mM
2-mercaptoethanol) at 37°C in a 5% CO2. THP-1 cells were
plated in 24-well plates at a density of 106 cells per well and
treated with 30 ng/mL of phorbol myristate acetate (PMA).
One day after stimulation with PMA, adherent cells were
maintained in the same media without PMA for an additional
3 days and used as a source of MΦs. The MPs were kept
under UV light overnight prior to exposure to cells for
sterility. They were suspended in complete RPMI 1640 media
to have a concentration of 3×106 particles per well. Varying
particle suspensions were added to constant cell numbers
depending upon the experiments and incubated for 24 h.
Control groups consisted of untreated cells and cells receiving
MDP and TDB solutions.
Macrophage Activation and Biochemical Assays
Cell morphology after MP exposure was observed by
phase contrast microscopy (Olympus IMT2, Lake Success,
NY, USA). TNF-α concentrations in culture supernatants
were determined using a commercial ELISA kit (BioSource
Europe S. A., Nivelles, Belgium). The enzymes ALP, LDH,
and NAG are widely used markers for tissue damage, cell
lysis, and phagocytic activity, respectively. Cell death by
necrosis is typically measured by assays for plasma membrane
permeability such as LDH assay. Assays for these markers
were performed on cell-free supernatant with modifications
for use on the Cobas Fara II Autoanalyzer (Hoffman-
LaRoche Branchburg, NJ, USA). Activities of ALP and
LDH were assayed using commercially available kits from
Sigma (St. Louis, MO, USA) and NAG levels were deter-
mined by a kit from Boehringer Mannheim (Indianapolis, IN,
USA). Each formulation was tested at least in triplicate.
MTT Cell Viability Assay
The viability of the cells were evaluated by the reduction
of yellow MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tet-
razolium bromide) to purple formazan. THP-1 cells (1.8×105
cells per well) were plated in 96-well plates and stimulated
with PMA as described above. This assay provides a sensitive
measurement of the normal metabolic state of cells,
particularly that of mitochondria, and hence, is an indication
of early cellular changes. Differentiated THP-1 cells were
exposed to MPs at various concentrations for 24 h. MPs were
uniformly suspended in media (with antibiotics) before
replacing the original media in the 96-well plate with the
MP suspension. Final MP numbers achieved were one, five,
ten, and 30 per three THP-1 cells (100 μL per well) for all the
exposure groups. Controls consisted of cells incubated in the
absence of any formulations. After removing the media, cells
in each well were incubated with MTT in phenol red-free
RPMI 1640 media for 3.5 h according to the manufacturer’s
protocol. The assay was stopped by adding MTT solubilization
solution (10% Triton X-100, 0.1 N HCl in anhydrous
isopropanol). The plates were stored overnight at 37°C to
completely dissolve formazan crystals. The formazan was
quantified using Bio-Rad Model 3550 microplate reader
(Bio-Rad Laboratories, Hercules, CA, USA) to measure the
absorbance at a wavelength of 570 nm and background
absorbance at 690 nm. Results of cell viability were
calculated as the percentage of formazan formed by cells
coincubated with MPs with respect to the formazan formed
after incubation of cells in a particle-free medium.
Statistical Evaluation
The data were analyzed by one-way analysis of variance
for multiple comparisons (Dunnett’s t tests) with P<0.05.
SAS software version 8.2 (SAS institute, Cary, NC, USA) was
used for statistical analysis.
RESULTS
Characterization of MPs
MPs analyzed for particle size by laser diffraction
produced unimodal or bimodal distributions indicating some
agglomeration with median volume diameters between 4 and
6 μm. This confirms the size range expected for particles to be
engulfed by dedicated phagocytic APCs including AMΦs
(Fig. 1; Table I).
The MP morphology in SEM micrographs (Fig. 2) was
influenced by the adjuvant encapsulated. The spray-drying
procedure produced PLGA and PLGA-MDP MPs that
were wrinkled and had collapsed perforated hollow sphere
appearance.
The particle densities obtained by tap density method
and the cascade impactor were similar with densities of 0.1–
0.3 mg/mL; PLGA-TDB MPs were more dense than PLGA-
MDP MPs. Encapsulation efficiency between 86% and
100% was achieved for MDP in MPs as estimated by HPLC
(Table I).
Morphology
When exposed to MPs, THP-1 cells demonstrated signs
of activation after 24 h incubation based on morphological
changes as shown in Fig. 3. THP-1 cells exposed to PLGA
particles, 0.1% MDP and TDB MPs, and 1% MDP-TDB MPs
(Fig. 3b–e, respectively) had extensive cellular extensions and
elongated morphology, suggesting that theses cells were
activated and phagocytosed the particles. Extensive cellular
extensions were not observed in control cells (Fig. 3a).
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Macrophage Activation upon MP Uptake
TNF-α activity in the culture supernatant of cells
exposed for 24 h to MPs was determined. TNF-α secretion
increased by treating THP-1 cells with either PLGA MPs
alone (192.70±24.05 pg/mL) or different concentrations of
PLGA-MDP MPs. PLGA-MDP 0.1% (244.81±12.63 pg/mL),
PLGA-MDP 0.5%, and PLGA-MDP 1% MPs had higher
TNF-α release than PLGA-TDB MPs (Fig. 4).
Substantial LDH was released following exposure to
PLGA alone (87.15 IU/L), PLGA-MDP 0.1% (93.79 IU/L),
and PLGA-MDP 0.5% MPs (90.51 IU/L) than TDB MPs and
control (Fig. 5) (P<0.05).
NAG release was statistically higher following PLGA
alone (22.73 IU/L) and PLGA-MDP 0.1% and 0.5% MPs
exposure (23.24 and 21.98 IU/L, respectively) compared to
control cells (Fig. 6) (P<0.05).
The ALP levels from the cells exposed to PLGA-MDP
and PLGA-TDB MPs showed no significant difference
compared to the control values.
Cytotoxicity Studies
MTT assays were conducted on THP-1 cells after
exposure to the MPs. Figure 7 compares the effect that MPs
have on the metabolic state of the cells over a 24-h exposure
period, showing the cellular viability as a function of both
formulation type and dosage level. The general cellular
viability of AMΦs was estimated with respect to the addition
of either blank MPs or mycobacterial adjuvants entrapped in
MPs. PLGA and PLGA-TDB 0.1% MPs at less than ten
particles per three cells produced more formazan than control
resting cells, which may be indicative of an activation of the
metabolic state of the cells. All particles showed cell








SEM Volume diameter distribution
Projected area median
diameter (μm) GSD Dv50 (μm) Span
PLGA – N.A. 0.133 3.66 1.36 6.29 1.60
PLGA-MDP 0.1 94.5 0.129 3.25 1.37 6.41 1.61
PLGA-MDP 0.5 86.3 0.162 3.16 1.39 5.70 1.41
PLGA-MDP 1 102.7 0.169 3.86 1.41 5.57 1.48
PLGA-TDB 0.1 N.D. 0.343 2.73 1.31 3.94 1.14
PLGA-TDB 1 N.D. 0.220 3.35 1.33 6.07 1.41
PLGA-MDP-TDB 1 N.D. 0.161 4.35 1.40 5.72 1.36
N.A. not applicable, N.D. not determined, GSD geometric standard deviation
Fig. 1. Volume particle size distribution of PLGA (a), PLGA-MDP 1% (b), PLGA-TDB 1% (c), and
PLGA-TDB-MDP 1% (d) determined by laser diffraction
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viabilities above 84% except PLGA-TDB 1% MPs exposed
to one particle per three cells (cell viability 72%). Thus, no
formulation showed detectable decrease in cell viability in all
dosages used.
DISCUSSION
The objective of this study was to screen potential
adjuvants entrapped in MPs for their effect on phagocytic
Fig. 3. Activation of THP-1 cells after 24 h incubation with the microparticles: control or no treatment (a); PLGA particles (b); PLGA-MDP
0.1% particles (c); PLGA-TDB 0.1% particles (d); PLGA-TDB-MDP 1% particles (e). Photographs taken at ×40 magnification
Fig. 2. SEM micrographs of PLGA particles (a), PLGA-MDP 0.1% particles (b), PLGA-TDB 1%
particles (c), and PLGA-TDB-MDP 1% particles (d). Scale bar represents 10 μm
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APCs following administration by the pulmonary route.
Therefore, the cytotoxicity of MDP and TDB immunomodu-
lators entrapped in biodegradable PLGA polymer in THP-1
cells was assessed. Most of the antigens showing protection in
animal models have been effective when administered with a
Th1-inducing adjuvant (18).
PLGA particles containing MDP and TDB immunomo-
dulators may act as adjuvants when targeted to AMΦs in the
lungs, causing cell activation. These activated MΦs may
trigger multiple microbicidal mechanisms, including phagoly-
sosomal fusion, respiratory burst, and the production of
proinflammatory cytokines, which restrict the growth of
ingested organisms and the recruitment of additional immune
cells (19,20). This phenomenon may also lead to the initiation
of a Th1-mediated immune response (21). Targeting immu-
nomodulators to AMΦs could also contribute to the reduc-
tion in toxicity observed in other pulmonary cells. Cellular
and biochemical changes in THP-1 cells could serve as
markers for pulmonary injury induced by these particles.
The electron micrograph images of these MPs indicated
that they were perforated collapsed hollow spheres consistent
with their low densities. The production of such particles is
known to be possible from the adoption of specific process-
ing parameters for spray-drying (22). The volume median
diameters, obtained by laser diffraction, of these MPs were
larger than the projected area diameters obtained from
SEM, consistent with the presence of agglomerates in the
formulations.
It is known that materials incorporated in PLGA MPs
show extended dissolution profile. MDP and TDB incorpo-
rated in MPs may, thus, show extended release inside MΦs
and exhibit sustained immune response. Once phagocytosed,
Fig. 5. Measure of LDH activity (mean±SD) on the culture medium
of cells after 24 h exposure to different formulations. Data expressed
as mean values±SD of the means from studies conducted in triplicate.
*P<0.05 of LDH compared with negative controls (Dunnett’s t test
was used)
Fig. 6. Release of NAG from THP-1 cells after exposure to micro-
particles for 24 h. Data expressed as mean values±SD of the means
from studies conducted in triplicate. *P<0.05 of NAG compared with
negative controls (Dunnett’s t test was used)
Fig. 4. Release of TNF-α in the culture supernatant. Data expressed
as mean values±SD of the means from studies conducted in triplicate.
*P<0.05 of TNF-α compared with negative controls (Dunnett’s t test
was used)
Fig. 7. Cell viability of THP-1 cells exposed to one (white fill), five
(hatched fill), ten (gray fill), and 30 (black fill) MPs per three cells for
24 h with different microparticle formulations of MDP and TDB
using MTT assay. The data expressed as mean±SD of triplicate
experiments per condition and are expressed as a percentage of the
control value
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the majority of particles are trafficked within the cell for
periods that may be sufficient for clearance by MΦ migration
from the lungs (23,24). Thus, it is anticipated that particle
clearance is linked to the rate of degradation of the particles
in the intracellular compartments and to the exit of AMΦs
from the lungs leading to sustained release of the molecules
within AMΦs.
These MPs are not expected to induce any cytotoxicity
due to the biodegradable nature of the polymer. MDP has
been reported to be a potent immunoadjuvant that enhances
antigen processing by stimulating immune-component cells,
such as monocytes and MΦs (25). Therefore, it is anticipated
that MDP and TDB MPs will serve as effective adjuvants.
Human monocytic THP-1 cells can be differentiated into
mature MΦ-like cells and develop AMΦ-like functions in
response to PMA. It has been shown that differentiated THP-
1 cells closely model the behavior of primary human AMΦs
in various aspects (26). Differentiated THP-1 cells adhere to
dish surfaces (27) and resemble primary MΦs in morphology.
Mechanistic studies using human AMΦs have been challeng-
ing because of the difficulty of obtaining these cells in large
numbers and, in addition, their appearance in a homogeneous
population of cells. Cytokine production is highly variable
among human donors, and apoptosis does not proceed in a
synchronous manner, making experiments difficult to inter-
pret. We, therefore, selected the THP-1 cell line as a
representative model for studying functional, biochemical,
and morphological changes in MΦs.
TNF-α appears to have numerous protective functions in
TB, but there are instances where it causes tissue damage
similar to human disease (28). However, it should be noted
that, in the broader context of immunization, TNF-α is known
to have positive implications. It is required for the formation
and maintenance of granulomas, in animal models of TB
(29,30), and for the control of latent TB, in humans (31).
TNF-α supports apoptosis of MΦs infected with Mtb, thereby
contributing to the clearance of the pathogen (32). TNF-α
promotes the maturation of dendritic cells, thereby inducing
the transport of mycobacterial antigens to the lymph nodes
and the priming of T cell subsets that traffic to the site of
infection to complement effector mechanisms of innate
immunity. TNF-α has also been reported to increase MΦ
phagocytosis and activation, leading to the induction of a Th1
immune response. An increase in TNF-α release was
observed in cells treated with MDP and PLGA MPs in
comparison to TDB MPs as depicted in Fig. 4. TDB MPs
(0.1% and 1.0%) and solution (100 μg/mL) both had
significantly lower TNF-α release. Additional in vivo
studies are required to establish the beneficial or deleteri-
ous effects of TNF-α release in response to the presence of
MDP MPs.
In our previous studies, we had shown that the inclusion
of TDB (0.1% w/w) in PLGA-Ag85B MPs enhanced their
adjuvant effect when administered to infected AMΦ cells as
indicated by the release of the cytokine IL-2 (33). TDB in
combination with the cationic surfactant dimethyl dioctadecyl
ammonium bromide promoted an immune response similar
to potential TB vaccines against Mtb infection in a murine
model (34). This combination of TDB and cationic surfactant
has also been effective in the more sensitive guinea pig model
of TB infection (35).
THP-1 cells exposed to MDP and TDB MPs exhibited
altered morphology relative to controls. Enzyme levels of
NAG and LDH were elevated in the case of cells exposed to
MDP MPs compared to TDB MPs, indicating a nonspecific
potentially cytotoxic response.
The in vitro cytotoxicity of these immunomodulators
formulated in biodegradable MPs were quantified by the
release of cytosolic enzyme LDH into cell culture medium as
the marker for membrane integrity and the MTT assay
representing the metabolic and mitochondrial activity of
treated cells. LDH is a stable cytoplasmic enzyme stored in
viable cells and any increase in its leakage indicates that the
integrity of cell membranes is compromised, possibly due to
oxidative injury (36). The TDB MPs (0.1% and 1.0%) and
TDB-MDP MPs (1.0%) both had significantly lower LDH
release than MDP-only MPs. The leakage of LDH to the
outside media shows that MDP MPs leads to higher loss of
membrane integrity compared to TDB MPs. For the MTT
assay, all cells showed viabilities above 84% except 1.0%
TDB MPs (exposed to one particle per three cells) which had
a lower viability of 72%. There were no significant differences
between MDP and TDB particles when assayed by MTT.
These results showed that the LDH assay was more
sensitive than the MTT assay. Lower concentrations of MDP
in MPs caused greater changes in LDH release compared
with their effects on mitochondrial dehydrogenase activity by
MTT assay. This may suggest that mitochondria may not be a
primary target for MDP released from MPs. MDP MPs may
interact with the plasma membrane causing cell lysis but may
not be significantly taken into cells thus not reaching
intracellular targets such as mitochondria and impairing their
functions. MDP may cause a progressive accumulation in the
phospholipid bilayer resulting in disruption of the membrane
architecture and lysis. Thus, the LDH test provides valuable
additional information to that generated by the MTT test.
The LDH test is widely used in modern toxicology; hence,
there is great value in using the combined approach of MTT
and LDH.
The increase in NAG release relative to LDH can be
used to estimate how much of this increase in NAG is due to
lysed cells (increase in both NAG and LDH enzymes) and
how much is due to stimulated phagocytic cells (increase in
NAG only). PLGA MPs, PLGA-MDP MPs (0.1% and
0.5%), as well as MDP solution showed higher levels of both
NAG and LDH release, suggesting MDP causes more cell
lysis than TDB MPs.
Exposure time may also significantly influence apparent
cytotoxicity of these MPs. In the present study, differentiated
THP-1 cells were exposed to a variety of MP concentrations
containing MDP and TDB for 24 h. Though we did not
evaluate different exposure times, it may be suggested that
the maximal release of these immunomodulators was essen-
tially complete in 24 h and that the most toxic effects occurred
during the first 24 h. We had previously demonstrated that
approximately 85% of MDP was released from MPs in a
linear fashion with respect to time over the first 24 h
reflecting the release of surface associated adjuvant (33) and
phagocytosis by AMΦs occurred within 6 h after particle
exposure (37). Since the supernatant sampling was performed
at 24 h, it is reasonable to assume that 75–80% of
immunomodulators were presented to the AMΦs. However,
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the initial rapid release is followed by extended release of the
remaining adjuvant. PLGA formulated MPs are known to
release measurable amounts of compounds for periods
beyond 24 h, although the rate of release decreases with time
due to the significantly depleted reservoir of the active
ingredient (38).
CONCLUSION
TB being an insidious worldwide disease of immense
significance, new approaches to delivery and effectiveness of
vaccines to treat this disease is desirable. Two potential
adjuvants, MDP and TDB, were encapsulated in polymeric
MPs. These particles were prepared in sizes suitable for
aerosol delivery to the lungs and appeared to be perforated
collapsed hollow spheres. Further work is required to study
the relevance of the statistical increases in biochemical
markers of adverse effects evident from the in vitro studies
to the function of AMΦs in vivo and the impact on the
surrounding tissues using different animal species following
the administration of immunomodulators.
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